Key Development AstraZeneca says it is adjusting its pricing strategy for future medicines as the pharmaceutical industry responds to the... Read more
Category: Uncategorized
BOSTON SCIENTIFIC’S RESTRUCTURING PLAN REFLECTS A NEW PHASE OF OPERATIONAL DISCIPLINE IN THE MEDTECH INDUSTRY
Key Development Boston Scientific has approved a new company-wide restructuring programme designed to streamline operations, improve cost efficiency, and support... Read more
GLOBAL HIV FUNDING DECLINE THREATENS TO REVERSE DECADES OF PROGRESS IN THE FIGHT AGAINST AIDS
Key Development A new report from UNAIDS warns that the global response to HIV is entering a critical phase after... Read more
POTENTIAL WIDESPREAD CYCLOSPORA CONTAMINATION IN CENTRAL MEXICO RAISES NEW QUESTIONS ABOUT GLOBAL FOOD SAFETY OVERSIGHT
Key Development A new assessment from former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb suggests the ongoing cyclosporiasis... Read more
JOHNSON & JOHNSON’S US$5.5 BILLION TALC SETTLEMENT MARKS A PIVOTAL SHIFT IN PHARMACEUTICAL LITIGATION STRATEGY
Key Development Johnson & Johnson has announced a proposed US$5.5 billion settlement to resolve approximately 69,000 remaining lawsuits alleging that... Read more
ASTRAZENECA FACES A NEW TEST OF ITS GROWTH STRATEGY AS RARE DISEASE EXPANSION ENCOUNTERS A CLINICAL SETBACK
Key Development Not every late stage clinical failure changes the trajectory of a pharmaceutical company, but every unsuccessful trial provides... Read more
NATIONWIDE COSMETIC RECALL HIGHLIGHTS THE GROWING IMPORTANCE OF QUALITY ASSURANCE IN VIETNAM’S PERSONAL CARE MARKET
Key Development Vietnam's Drug Administration has ordered a nationwide recall of two cosmetic product batches including Oatrum body cleansing gel... Read more
GERMANY’S SICK LEAVE CRACKDOWN HIGHLIGHTS DEEPER CHALLENGES FOR HEALTHCARE AND WORKFORCE PRODUCTIVITY
Key Development Germany is considering stricter oversight of employee sick leave as rising absenteeism and labour costs fuel concerns among... Read more
ARGENX’S $2.2 BILLION FORTE ACQUISITION SIGNALS A NEW WAVE OF IMMUNOLOGY CONSOLIDATION
Key Development Argenx has agreed to acquire Forte Biosciences in a transaction valued at approximately $2.2 billion, representing one of... Read more









